Efficacy of Carraguard®-Based Microbicides In Vivo Despite Variable In Vitro Activity
Stuart G. Turville, Meropi Aravantinou, Todd Miller et al. · 2008
Read Efficacy of Carraguard®-Based Microbicides In Vivo Despite Variable In Vitro Activity by Stuart G. Turville, Meropi Aravantinou, Todd Miller et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0003162.txt.
Introduction
Stuart G. Turville, Meropi Aravantinou, Todd Miller and colleagues test Carraguard-based microbicides against HIV in this 2008 PLOS ONE paper. Anti-HIV microbicides were in clinical trials, and knowing how a promising approach works in the body, alongside proof that it works in vivo, is central to better next generation products. The team evaluated Carraguard and a new Carraguard-based formulation.
The title reports efficacy in vivo despite variable activity in vitro, in lab tests. Readers see why lab results alone can mislead for prevention gels. The study stresses testing protection in living systems before judging a microbicide a success or failure.
Catalog record
| CREATOR | Stuart G. Turville, Meropi Aravantinou, Todd Miller et al. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003162
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Efficacy of Carraguard®-Based Microbicides In Vivo Despite Variable In Vitro Activity Authors: Stuart G. Turville, Meropi Aravantinou, Todd Miller, Jessica Kenney, Aaron Teitelbaum, Lieyu Hu, Anne Chudolij, Tom M. Zydowsky, Michael Piatak, Julian W. Bess, Jeffrey D. Lifson, James Blanchard, Agegnehu Gettie, Melissa Robbiani Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0003162 ABSTRACT Anti-HIV microbicides are being investigated in clinical trials and understanding how promising strategies work, coincident with demonstrating efficacy in vivo , is central to advancing new generation microbicides. We evaluated Carraguard® and a new generation Carraguard-based formulation containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 (PC-817). Since dendritic cells (DCs) are believed to be important in HIV transmission, the formulations were tested for the ability to limit DC-driven infection in vitro versus vaginal infection of macaques with RT-SHIV (SIVmac239 bearing HIV reverse transcriptase). Carraguard showed limited activity against cell-free and mature DC-driven RT-SHIV infections and, surprisingly, low doses of Carraguard enhanced infection. However, nanomolar amounts of MIV-150 overcame enhancement and blocked DC-transmitted infection. In contrast, Carraguard impeded infection of immature DCs coincident with DC maturation. Despite this variable activity in vitro , Carraguard and PC-817 prevented vaginal transmission of RT-SHIV when applied 30 min prior to challenge. PC-817 appeared no more effective than Carraguard in vivo , due to the limited activity of a single dose of MIV-150 and the dominant barrier effect of Carraguard. However, 3 doses of MIV-150 in placebo gel at and around challenge limited vaginal infection, demonstrating the potential activity of a topically applied NNRTI. These data demonstrate discordant observations when comparing in vitro and in vivo efficacy of Carraguard-based microbicides, highlighting the difficulties in testing putative anti-viral strategies in vitro to predict in vivo activity. This work also underscores the potential of Carraguard-based formulations for the delivery of anti-viral drugs to prevent vaginal HIV infection. INTRODUCTION Education and condom use can help limit HIV-1 transmission [1] – [3] , but as currently applied do not represent definitive solutions. Thus, additional strategies are required to stem the spread of infection [4] . Vaccine and microbicide strategies tested to date have not been successful [5] – [8] . In light of recent setbacks in vaccine research [9] , there is an even greater need to identify alternative approaches that reduce the risk of acquiring HIV-1 infection. Microbicides, operationally defined as substances intended to reduce or prevent transmission of HIV and/or other sexually transmitted infections (STIs) when applied topically to genital mucosal surfaces ( www.microbicide.org ), represent one such option. While the efficacy of a topically applied microbicide is likely to depend on the timely and correct application of the product relative to potential exposure, the availability of such products still represents an important strategy that could help stem the spread of HIV-1. Experience with such products may also usefully inform the development of alternative, coitus independent strategies. Development of current and future microbicides must take into account our cumulative knowledge of HIV transmission. The early events leading to HIV passage across the genital mucosa likely involves HIV capture by a wide variety of molecules on the surface of epithelial cells and/or leukocytes followed by infection of permissive target cells within the tissues. In vitro virus transmission models have shown that dendritic cells (DCs) can capture virus and efficiently transmit these virions to CD4 T cells across infectious synapses between DCs and T cells [10] – [14] . CCR5-using HIV (R5 HIV) can productively infect immature DCs, like those located at the body surfaces, with the newly produced viruses being readily transferred to T cells [15] . In addition, both immature and mature DCs can effectively internalize viruses and transfer these virions to T cells, in the absence of productive infection of the DCs [10] – [12] , [14] , [16] – [18] . It is likely that immediate capture of virus by mucosa-associated DCs then transmits the virus to CD4 T cells, where robust virus replication occurs [10] , [15] , [19] , consistent with other evidence for a more dominant role for CD4 T cells in the subsequent amplification of virus [20] – [22] . Thus, we postulated that the ability of candidate compounds to block infection in DCs or DC-T cell co-cultures may provide a more rigorous and relevant in vitro evaluation of the capacity of potential microbicide formulations. Microbicide strategies currently being explored include broad-acting formulations that block HIV attachment (e.g., Carraguard, Pro 2000, BufferGel), specific small molecule inhibitors that target viral or cellular molecules critical for virus attachment, entry, or fusion (e.g., CCR5 inhibitors, fusion inhibitors like T-1249, anti-envelope Abs), and anti-viral drugs (e.g., PMPA, TMC-120, UC-781, MIV-150) [23] . The appeal of the broad-acting compounds is that they should prevent HIV interactions with any cell type (independent of the molecules involved) while also potentially having activity against other STIs. Carraguard, is a representative of this group, and has been shown to have potent activity against X4 HIV isolates with more limited activity against R5 HIV isolates in vitro [24] – [30] , as well as having activity against other STIs [31] – [36] . A recently completed Phase III efficacy trial testing the ability of Carraguard to prevent HIV infection in women revealed that Carraguard is safe and while the frequency of HIV infection was lower in the Carraguard arm (134 vs 151 seroconversions in the placebo group), this was not a statistically significant difference [8] . In addition to safety, the inherent rheological properties and stability profile of Carraguard renders it a promising formulation vehicle, which may also have some anti-viral activity, to which other anti-viral agents could be added to provide a more effective microbicide. The aim of this study was to evaluate the capacity of a microbicide (PC-817) comprised of Carraguard and the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 to inhibit DC-driven infection in vitro and prevent vaginal immunodeficiency virus infection in macaques. MIV-150 (developed by Medivir, AB, Sweden, and licensed to the Population Council) is a tight-binding NNRTI with a rapid association and slow dissociation rate, which has activity against a variety of HIV-1 isolates, as well as HIV-2 [37] . MIV-150 also has virucidal activity against cell-free HIV and its anti-viral activity is not affected by seminal fluid [37] . We provide the first evidence of the additive effects of Carraguard and MIV-150 against DC-mediated infections in vitro and demonstrate the efficacy of Carraguard-based gels and topically applied MIV-150 in vivo . MATERIALS AND METHODS Cell culture and reagents: SUPT1/CCR5 CL.30 cells (provided by J. Hoxie, University of Pennsylvania) and 174×CEM cells (AIDS Research and Reagent Program, courtesy of Peter Cresswell) were maintained in RPMI 1640 (Cellgro; Fisher Scientific, Springfield, N.J.) with 10% (v/v) heat-inactivated fetal calf serum (FCS, Cellgro). The TZM.bl cell line (AIDS Research and Reagent Program, courtesy of Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc) was maintained in DMEM (Cellgro) with 10% (v/v) heat-inactivated FCS. Peripheral blood mononuclear cells (PBMCs) were isolated from HIV seronegative leukocyte-enriched preparations purchased from the New York Blood Center using Ficoll-Hypaque density gradient centrifugation (Amersham Pharmacia Biotech, Uppsala, Sweden). Monocytes were isolated using CD14 magnetic cell sorting (Miltenyi Biotec, Auburn, CA), with washing and elution in cold 1× PBS supplemented with 1% AB human serum